Holen Sie sich die Stockscreener-App
2.04
7.37%
0.14
Handel nachbörslich:
1.95
-0.09
-4.41%
Schlusskurs vom Vortag:
$1.90
Offen:
$1.91
24-Stunden-Volumen:
882.17K
Relative Volume:
1.58
Marktkapitalisierung:
$73.34M
Einnahmen:
$210.70K
Nettoeinkommen (Verlust:
$-21.37M
KGV:
-1.8545
EPS:
-1.1
Netto-Cashflow:
$-21.10M
1W Leistung:
+0.99%
1M Leistung:
+22.89%
6M Leistung:
+9.09%
1J Leistung:
-13.19%
1-Tages-Spanne:
$1.80
$2.09
1-Wochen-Bereich:
$1.80
$2.20
52-Wochen-Spanne:
$1.41
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Vergleichen Sie GANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.04 | 68.30M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Intraday pattern recognizer results for Gain Therapeutics Inc.Weekly Trend Report & Risk Controlled Daily Trade Plans - newser.com
Institutional scanner results for Gain Therapeutics Inc.Earnings Beat & Accurate Technical Buy Alerts - newser.com
Certain Options of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
How risky is Gain Therapeutics Inc. stock nowWeekly Profit Report & Safe Entry Point Identification - newser.com
Is Gain Therapeutics Inc. still worth holding after the dip2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Will Gain Therapeutics Inc. stock benefit from sector rotationEarnings Trend Report & Weekly High Return Forecasts - newser.com
How to build a dashboard for Gain Therapeutics Inc. stockJuly 2025 Fed Impact & Advanced Technical Analysis Signals - newser.com
Is Gain Therapeutics Inc. stock entering bullish territory2025 Historical Comparison & Smart Investment Allocation Tips - newser.com
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
What does recent volatility data suggest for Gain Therapeutics Inc.Earnings Miss & High Return Trade Opportunity Guides - newser.com
How to forecast Gain Therapeutics Inc. trends using time seriesTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
Published on: 2025-10-10 04:06:35 - newser.com
Eric Richman Resigns from Gain Therapeutics Board - TipRanks
Allosteric small molecule therapies in PD, with Gene Mack - pharmaphorum
Is Gain Therapeutics Inc. stock cheap at current valuationBreakout Watch & Daily Stock Trend Watchlist - newser.com
Is it time to cut losses on Gain Therapeutics Inc.2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times
Gain Therapeutics to Host Virtual KOL Event on GT-02287 and Parkinson's Disease Research - Quiver Quantitative
Applying big data sentiment scoring on Gain Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - newser.com
Gain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Gain Therapeutics Supports Reliable Data Management In Labs - Kalkine Media
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Is Gain Therapeutics Inc a good long term investmentVolume Spike Alerts & Small Budget Big Profits - earlytimes.in
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics' GT-02287 Shows UPDRS Improvement in 9 by Day 90 | GANX Stock News - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat
Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com
Does Gain Therapeutics Inc. stock trade at a discount to peers2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Gain Therapeutics (NASDAQ:GANX) versus Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head Review - Defense World
What moving averages say about Gain Therapeutics Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Applying Wyckoff theory to Gain Therapeutics Inc. stockWall Street Watch & Free Community Supported Trade Ideas - newser.com
Analyzing drawdowns of Gain Therapeutics Inc. with statistical tools2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):